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Objectives: Evidence has implicated a possible role of tumor mutation status on local 
control (LC) with radiotherapy. BRAF is a proto-oncogene that is mutated in approximately 
50% of patients with melanoma. We sought to analyze the influence of BRAF status on 
LC of melanoma brain metastases (MBM) following Gamma Knife radiosurgery (GK).
Methods: Among 125 patients treated with GK for MBM at our institution between 2006 
and 2015, we identified 19 patients with 69 evaluable metastases whose BRAF mutation 
status was known and follow-up imaging was available. LC of individual metastases 
was compared based on BRAF mutation status using statistical techniques to control 
for measurements of multiple metastases within each patient. CNS progression was 
defined as either local failure or development of new lesions.
results: Of the 69 metastases, BRAF was mutated in 30 and wild-type in 39. With a 
median follow-up of 30 months for all patients and a median follow-up of 5.5 months for 
treated lesions, 1-year LC was significantly better among metastases with mutated vs. 
wild-type BRAF (69 vs. 34%, RR = 0.3, 95% CI = 0.1–0.7, p = 0.01). BRAF mutation 
was found to be a significant predictor of LC after stereotactic radiosurgery (SRS) in 
both univariate [RR = 0.3 (95% CI 0.1–0.7, p = 0.01)] and multivariate [RR = 0.2 (95% CI 
0.1–0.7, p = 0.01)] analyses. There was also a trend toward improved CNS progression 
free survival (PFS) at 1 year (26 vs. 0%, p = 0.06), favoring BRAF-mutated patients.
conclusion: In this retrospective study, MBM treated with GK had significantly improved 
LC for patients with BRAF mutation vs. wild-type. Our data suggest that BRAF mutation 
may sensitize tumors to radiosurgery, and that BRAF wild-type tumors may be more 
radioresistant.
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inTrODUcTiOn
Melanoma is the fifth most common malignancy in the US, but the third most common cause of 
brain metastases. Of the estimated 75,000 people diagnosed annually with melanoma, 7.4–10% will 
develop brain metastases (1–3). Among patients presenting with stage IV melanoma, over 40% have 
or will develop brain metastases (4). Patients with melanoma brain metastases (MBM) have a 95% 
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chance of dying from their intracranial disease with a median 
survival time of 6.7 months (3, 5). Treatment for MBM includes 
surgical resection, stereotactic radiosurgery (SRS), whole brain 
radiation therapy (WBRT), steroids, or a combination of these. 
In patients with few, asymptomatic metastases, initial treatment 
with SRS alone is preferred (6–8). However, approximately 30% 
of MBM fail locally after SRS (9–11).
Response to SRS for brain metastases depends on several fac-
tors. Tumor histology, size, and marginal dose are well-established 
predictors of local control (LC) (9–13). Emerging evidence sug-
gests that the mutation status within a particular tumor may also 
influence LC after SRS. Johung et al. analyzed non-small cell lung 
cancer (NSCLC) patients with brain metastases treated with SRS 
and found that tumors with EGFR mutations or EML4–ALK trans-
locations rarely recurred in-field, whereas those that lacked such 
mutations or harbored KRAS mutations were more likely to expe-
rience in-field recurrence (14). Other researchers also reported 
higher response rates to brain radiation among NSCLC patients 
with mutant EGFR compared to those with wild-type EGFR (15). 
EGFR and ALK mutations result in constitutive activation of the 
MAPK pathway, which may confer radiosensitivity (16).
Mutations in the BRAF gene have been reported in approxi-
mately 50% of the patients with melanoma (17, 18). The most 
common mutation, BRAF-V600E, results in substitution of the 
valine residue with glutamic acid, locking the kinase into a consti-
tutively active conformation. Because BRAF is also an important 
protein in the MAPK pathway, we hypothesized that BRAF 
mutation status may influence LC of MBM treated with SRS. We, 
therefore, identified melanoma patients treated with SRS at our 
institution and analyzed their outcomes based on BRAF mutation 
status.
MaTerials anD MeThODs
Patients
From a database of patients treated with Gamma Knife (GK) 
SRS at our institution, we identified patients treated for MBM. 
Patients were included in this study if their BRAF mutation was 
known and at least one posttreatment imaging follow-up was 
available. WBRT, given either before or after SRS, was allowed, 
however, tumors previously treated with GK or surgical resec-
tion were excluded. This study was approved by the institutional 
review board (IRB code number: 1501M60361).
BRAF Mutation
BRAF mutation was tested on tissue obtained from biopsy or 
resection of extra-cranial melanoma. Patients with mutant BRAF 
were eligible for treatment with BRAF inhibition. BRAF inhibi-
tion was given at the discretion of the medical oncologist. The 
majority of patients were treated with vemurafenib. One patient 
also received dabrafenib.
radiation Treatment
Gamma Knife stereotactic radiosurgery was performed using 
the Leksell Gamma Knife Model 4C (Elekta AB, Stockholm, 
Sweden). Radiation dose was selected, with modifications by 
the prescribing physician, based on tumor size according to the 
RTOG 9005 trial (19). In general, tumors measuring <2, 2–3, and 
3–4 cm received 24, 18, and 15 Gy, respectively, with doses gener-
ally prescribed to the 50% isodose line. WBRT was delivered from 
6-MV parallel-opposed beams at 30 Gy in 10 (n = 7) or 20 Gy in 
five fractions (n = 1).
Follow-up and endpoints
After GK SRS, patients were followed at 3-month intervals with 
magnetic resonance imaging (MRI) performed at each visit. 
Patient follow-up duration was defined as time from first GK to 
last imaging visit or death.
Tumor size was measured in three dimensions on axial, coro-
nal, and sagittal views of pretreatment and follow-up gadolinium-
enhanced T1 phase MRI. Tumor volume was estimated with the 
ellipsoid volume formula. The accuracy of this technique has 
previously been verified with respect to volume as measured by 
Leksell Gamma Plan (9). LC of individual metastases was based on 
modified RECIST criteria. A tumor was defined as locally failed if 
there was a relative increase in tumor volume on follow-up MRI 
by ≥20% compared to pretreatment MRI (9, 20). Necrosis or 
hemorrhage was included in volume quantification unless clearly 
present outside of the tumor. Lesions (n =  3) that returned to 
<20% of pretreatment MRI volume on subsequent imaging with 
only conservative management were considered controlled. The 
transient volume increase was interpreted as tumor swelling and/
or necrosis rather than treatment failure. CNS progression was 
defined for patients as either local failure of treated lesions or 
development of new lesions in the brain.
statistics
Patient demographic and treatment characteristics were com-
pared based on BRAF mutation status using the Chi-square test 
or Fisher’s Exact test for categorical variables based on expected 
cell counts. The general Wilcoxon test was used for continuous 
variables. Follow-up was measured by reverse Kaplan–Meier 
curves. CNS progression-free survival (PFS) and overall survival 
(OS) were calculated from the date of first GK to the date of pro-
gression or death, and were estimated with Kaplan–Meier curves. 
Comparisons were completed with the log-rank-test.
Local control was analyzed for individual metastases using 
two methods, both of which accounted for assessment of multiple 
metastases within each patient. First, crude LC at 3 and 6 months 
was estimated using a non-linear mixed logistic regression. 
The correlation of clustering of metastases within patients was 
modeled assuming a normally distributed random variance 
component (21). All metastases were evaluable for the 3-month 
assessment. Fifteen metastases were excluded from the 6-month 
assessment due to lack of imaging. Second, LC was estimated 
with Kaplan–Meier curves and compared with a Frailty–Cox 
model accounting for within-cluster correlation by incorporating 
cluster effects as independent and identically distributed random 
variables (22). LC was censored for early patient death or loss of 
follow-up. Although patient numbers were small, we attempted to 
control for potential confounding of the effect of BRAF mutation 
on the risk of failure by use of multiple regression in the Frailty–
Cox model. Additional variables included in the model were use 
TaBle 1 | characteristics of patients by BRAF status.
Variable BRAF wild-type 
(N = 8)
BRAF-mutated 
(N = 11)
p-valuea
Median, age, and range 58 (42–73) 51 (32–78) 0.32
Gender: male 4 (50%) 5 (45%) 0.99
Presence of extra-cranial 
metastases
8 (100%) 9 (82%) 0.49
GPA 0.30
1 0 (0%) 2 (18%)
2 3 (38%) 2 (18%)
3 5 (63%) 4 (36%)
4 0 (0%) 3 (27%)
KPS 0.36
<70 0 (0%) 1 (9%)
70–80 4 (50%) 3 (27%)
90–100 4 (50%) 7 (63%)
Number of metastases at 
first GK
0.99
1 3 (38%) 5 (45%)
2 2 (25%) 2 (18%)
≥3 3 (38%) 4 (36%)
Median 2 (1–9) 2 (1–50)
Use of WBRT: yes 4 (50%) 4 (36%) 0.37
Median F/U (months) 26 (9–26) 32 (25–33) 0.87
ap-value for between-treatment comparisons. Continuous variables were analyzed by 
general Wilcoxon test. Categorical variables were analyzed by Fisher’s exact test.
TaBle 2 | characteristics of metastases by BRAF status.
BRAF wild-type 
(N = 39)
BRAF-mutated 
(N = 30)
p-valuea
Use of WBRT 31 (79%) 13 (43%) <0.01
GK as initial treatment 14 (36%) 3 (10%) 0.01
GK as salvage treatment 
after WBRT
17 (44%) 10 (33%) 0.39
Median treatment  
volume (mL)
2.1 (0.1–284.8) 0.8 (0.1–99.6) 0.45
Median max treatment 
dimension (cm)
1.0 (0.2–6.2) 0.8 (0.3–2.9) 0.15
Median marginal dose (Gy) 22 (15–24) 22 (12–24) 0.63
ap-value for between-treatment comparisons. Continuous variables were analyzed by 
general Wilcoxon test. Categorical variables were analyzed by the Chi-square test.
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of WBRT, marginal dose (<22 vs. ≥22 Gy), and maximum tumor 
dimension (<0.80 vs. ≥0.80 cm). Treatment volume was excluded 
from the model due to its high correlation with tumor dimension. 
All tests were two-sided and considered significant if p < 0.05. 
SAS 9.3 (SAS Institute, Cary, NC, USA) and R 3.0.2 (R foundation 
for Statistical Computing, Vienna, Austria) were used to perform 
all statistical analyses.
resUlTs
Patient characteristics
We identified 125 patients treated with GK for MBM at our 
institution since 2006. Of these, 104 patients had either unknown 
BRAF status (routine testing began in 2011) or inadequate 
follow-up imaging, and therefore, were excluded, leaving 19 
eligible patients. Of these patients, BRAF was mutated in 11 and 
wild-type in 8. Characteristics of these two groups of patients 
were similar with respect to age, gender, presence of extracranial 
metastases, GPA, number of metastases, use of WBRT and 
follow-up duration (Table  1). Of the 11 patients with mutant 
BRAF, all but one received a BRAF inhibitor at some point in 
their treatment course.
analysis of individual Metastases
Among the 19 eligible patients, a total of 69 tumors were treated 
with GK SRS and had adequate follow-up imaging. Of these, 39 
were from patients with wild-type BRAF and 30 were from patients 
with mutated BRAF. Characteristics of these metastases were 
compared based on BRAF status. Metastases from patients with 
wild-type BRAF were more likely to have been exposed to WBRT 
therapy before or after GK (79 vs. 43%, p <  0.01). Otherwise, 
there were no significant differences between the two groups 
(Table 2). The median treatment volume of individual tumors for 
wild-type vs. mutated BRAF was 2.1 mL (0.2–284.8 cc) vs. 0.8 mL 
(0.1–99.6 mL), p =  0.45. The maximum tumor dimension was 
1.0 cm (0.2–6.2 cm) vs. 0.8 cm (0.3–2.9 cm), p = 0.15, respectively. 
Median marginal dose was 22 Gy (12–24 Gy) for both groups, 
commonly prescribed to the 50% isodose line. Median follow-
up from GK to last follow-up MRI for individual tumor was 
5.5 months (range = 0.7–29.8 months). Of the 30 metastases with 
mutated BRAF, all but one metastasis were exposed to a BRAF 
inhibitor at some point in the treatment course. Regarding the 
timing of BRAF inhibitor treatment in relation to GK SRS, 2 were 
exposed before GK (by at least 13 days); 10 were exposed before, 
during, and after; 6 were exposed both before (>18  days) and 
after (>6 days), but held during GK SRS; and 11 were exposed 
after (>10 days).
Of the 69 metastases treated with GK, 41 achieved LC (59%) 
at a median follow-up of 5.5 months. The 3- and 6-month crude 
LC for all the treated tumors was 80 and 72%, respectively. When 
analyzed based on BRAF status, there was a trend for improved 
crude LC among metastases with mutated BRAF as follow-up 
time increased. At 3 and 6  months following treatment, crude 
LC was 72 vs. 90% (n = 69, p = 0.14) and 61 vs. 90% (n = 54, 
p = 0.08), respectively (Figure 1A). Since there was loss of infor-
mation in assessing LC beyond 6 months using mixed models, 
we also assessed LC with a Frailty model through 1 year, which 
can incorporate censored patients. With this method, there was 
a statistically significant improvement in LC among metastases 
with mutated BRAF. At 1  year, LC was 34 vs. 69% [RR =  0.3 
(95% CI 0.1–0.7, p = 0.01)] for BRAF wild-type vs. BRAF mutant 
metastases, respectively (Figure 1B).
Univariate and Multivariate analysis
We analyzed the factors affecting LC using univariate analysis 
(Table 3). In addition to BRAF mutation status being predictive 
of better LC, a higher marginal dose of ≥22 Gy was also asso-
ciated with improved LC (67 vs. 27% at 1  year, p =  0.03). On 
multiple regression analysis (Table 4), BRAF mutation remained 
an independent predictor of LC [RR =  0.2 (95% CI 0.1–0.7, 
p =  0.01)]. The p-value for the effect of marginal dose did not 
FigUre 1 | local control of metastases in patients with mutated compared to wild-type BRAF with (a) bar graph of crude local control at 3 and 
6 months and (B) Kaplan–Meier curve of overall local control through 12 months.
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reach significance. LC was not influenced by max tumor dimen-
sion or the use of WBRT. Because all but one metastasis with 
mutated BRAF were exposed to a BRAF inhibitor, analysis of LC 
with regard to exposure of targeted therapy was not conducted. 
However, we did analyze the timing of BRAF inhibitor exposure 
relative to GK SRS and found no correlation with LC among the 
29 metastases that received targeted therapy (Table 5).
Patient Outcomes
At a median follow-up of 30 months, the median OS for the entire 
group of patients was 21 months. Survival was not different based 
on BRAF mutation status. The median OS was 21  months for 
patients with wild-type or mutated BRAF, with a 2-year survival 
of 38% (95% CI 6–72%) vs. 45% (95% CI 17–71%), respectively 
(p = 0.92, Figure 2A). There was a trend toward improved CNS 
PFS among patients with BRAF mutation [26% (95% CI 4–56%) 
vs. 0% at 1  year, p =  0.06, Figure  2B]. The incidence of CNS 
progression for wild-type vs. mutated BRAF was 87% (95% CI 
58–99%) vs. 39% (95% CI 16–73%), respectively at 3  months 
(p = 0.11) and 100 vs. 74%, respectively, at both 6 and 12 months 
(p  =  0.06). The improved CNS PFS seen among the BRAF-
mutated patients appears to be primarily attributed to a better 
LC of GK-treated metastases. Of the 8 patients with wild-type 
BRAF, all patients failed at at least 1 treated local sites (2 local 
only, 6 local and distant), whereas of the 11 patients with mutated 
BRAF, only 5 patients experienced local failure (all of whom also 
had distant failure).
DiscUssiOn
In this retrospective study, we examined the LC of MBM treated 
with GK SRS with respect to BRAF mutation status. We found 
TaBle 4 | Multiple regression analysis of local control for metastases 
treated with gK srs.
Factora N # events relative risk of  
failure (95% ci)
p-value
BRAF 0.01 0.01
Wild-type 39 19 1.0
Mutated 30 7 0.2 (0.1–0.7)
WBRT 0.92
No 25 7 1.0
Yes 44 19 0.9 (0.3–3.0)
Marginal dose 0.07
<22 Gy 30 16 1.0
≥22 Gy 39 10 0.4 (0.2–1.1)
Max tumor dimension 0.89
<0.80 cm 29 16 1.0
≥0.80 cm 40 10 0.9 (0.3–2.5)
aTumor volume not included due to high correlation with tumor dimension.
TaBle 3 | Univariate analysis of local control for metastases treated with gK srs.
Factor N # events local control  
at 1 year (%)
Median months  
to failure
relative risk of  
failure (95% ci)
p-value
Overall 69 26 49 7.7
BRAF 0.01
Wild-type 39 19 34 4.5 1.0
Mutated 30 7 69 5.6 0.3 (0.1–0.7)
WBRT 0.19
No 25 7 65 2.7 1.0
Yes 44 19 40 6.2 1.9 (0.7–5.2)
Treatment volume (ml) 0.83
<1.0 34 14 52 7.4 1.0
≥1.0 35 12 44 4.5 1.1 (0.5–2.5)
Max tumor dimension (cm) 0.46
<0.80 29 16 55 7.6 1.0
≥0.80 40 10 45 4.5 1.4 (0.6–3.2)
Marginal dose 0.03
<22 Gy 30 16 27 5.3 1.0
≥22 Gy 39 10 67 3.9 0.4 (0.2–0.9)
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a significantly improved LC among metastases carrying BRAF 
mutation compared to those with wild-type BRAF. Among brain 
metastases harboring mutated BRAF, 1-year LC was 69%, whereas 
those with wild-type BRAF have an inferior LC of 34% (p = 0.01). 
There was also a trend toward improved CNS PFS among patients 
with mutated BRAF, which appears to be primarily due to better 
LC of GK-treated metastases.
Our finding that the presence of BRAF mutation is associated 
with an improved LC raises the possibility that BRAF mutation 
may directly influence radiosensitivity when these tumors are 
treated with SRS. This is in keeping with recent observation 
made in NSCLC, in which patients with EGFR mutations or 
EML4–ALK translocations experience a significantly better in-
field control compared to those without such mutations or those 
harboring KRAS mutations instead (14, 15). These mutations are 
similar to BRAF mutation in that they all result in constitutive 
activation of the MAPK pathway (16). The association could sug-
gest a common mechanism such as increased proliferative rate 
and thus increased susceptibility to radiation therapy.
To our knowledge, there is only one published study that also 
addressed the influence of BRAF mutation status on LC following 
SRS for MBM (23). The study included 52 melanoma patients 
with 185 treated brain metastases. Unlike our study, a difference 
in LC with regard to mutation status was not found. The 1-year 
LC was 67.1% among MBM in patients with wild-type BRAF and 
70.0% for MBM in patients with BRAF mutation. Instead, they 
found that the use of BRAF inhibitor was significantly associated 
with 1-year LC (85.0% with vs. 51.5% without) (23). All but one 
patient with mutant BRAF in our study received a BRAF inhibitor 
at some point during their treatment course. It is possible that the 
improved LC observed in our patients is entirely conferred by the 
use of a BRAF inhibitor.
Several other studies reported the use of BRAF inhibitors 
in the setting of brain radiation therapy. In a small series by 
Narayana et al., 12 patients with BRAF mutations were treated 
with either SRS or WBRT prior to or along with vemurafenib. A 
75% radiographic response was observed among index lesions, 
including a 48% complete response and a 27% partial response 
(24). In another study, 24 patients with 80 metastatic brain lesions 
were treated with SRS while on vemurafenib. LC at 6 months and 
1 year was 92 and 75%, respectively and was felt to be better than 
reported control rates among melanoma patients treated with 
SRS alone. The authors suggested that there may be a synergistic 
effect between BRAF inhibitors and SRS (25). However, neither 
study compared the outcome directly to BRAF-mutated patients 
not treated with an inhibitor. Therefore, the possibility still exists 
that BRAF mutation itself may impact radiosensitivity directly.
It is not clear whether or how BRAF inhibition acts syner-
gistically with SRS. In the aforementioned study by Ly et al., the 
majority of lesions were not treated with a BRAF inhibitor within 
a 30-day period before or after SRS. Among the remaining lesions, 
FigUre 2 | Kaplan–Meier curve of (a) overall survival and (B) cns progression-free survival among patients based on BRAF mutation status.
TaBle 5 | Univariate analysis of timing of BraF inhibitor on local control for metastases treated with gK srs.
Timing of BraF inhibitor use N # events local control  
at 1 year (%)
Median months  
to failure
relative risk of  
failure (95% ci)
p-value
After GK SRS 11 4 64 7.7 1.0 0.71
Before and after GK SRS 16 2 87 1.6 2.0 (0.2–17.8)
Before GK SRS 2 1 50 2.7 0.7 (0.1–4.0)
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a washout period of 7  days (range 1–20  days) was  instituted 
(23). However, the median elimination half-life is only 50 h for 
vemurafenib, and even shorter for dabrafenib (5  h) (26, 27). 
It is therefore difficult to account for the improved LC observed 
using a traditional radiosensitization model in which the drug is 
expected to be present at the time of radiation, as shown in vitro 
for melanoma cell lines (28, 29). We also analyzed the timing of 
BRAF inhibitor exposure on LC with SRS, and we did not observe 
any correlation. However, our sample size was small with only 29 
metastases receiving targeted therapy.
Another unresolved issue is in regard to the safety of the 
concurrent use of a BRAF inhibitor with SRS. An increased rate 
and severity of radiation dermatitis has been observed when 
BRAF inhibition is used concomitantly with conventionally 
fractionated radiotherapy. This has lead many investigators 
to transiently hold drug therapy for patients undergoing SRS. 
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However, the necessity and appropriate duration of the “wash-
out” period has not been established. In the study by Ly et al., 
the median washout period ranged from 1 to 20  days with a 
median of 7 days (23). In the study by Ahmed et al., patients 
were told to hold the drug for 2–3 days before and after SRS 
treatment (25). Yet in another study that primarily assessed the 
safety of concurrent treatment, 20 patients had no interruption 
of BRAF inhibitor while undergoing SRS. No cases of radiation-
induced necrosis and no scalp radiation dermatitis occurred. 
A relatively small rate of edema and hemorrhage was detected, 
which is not unexpected following SRS for MBM (30). This is 
in contrast to the study by Ly et al. that reported a significantly 
increased intratumoral hemorrhage risk among patients treated 
with a BRAF inhibitor. Given the 1-year freedom from intratu-
moral hemorrhage rate of only 39.3%, the authors recommend 
discontinuation of BRAF inhibitors for 1–2 weeks both before 
and after treatment, provided systemic disease is controlled 
(23). We did not observe an unexpectedly high rate of posttreat-
ment intratumoral hemorrhage among the 10 patients treated 
concurrently with a BRAF inhibitor. The presence of hemor-
rhage on MRI was not always commented upon by radiologist, 
and therefore, our number could be underreported. While these 
issues are being sorted out, it remains an attractive hypothesis 
that if BRAF mutation itself is associated with an enhanced 
radiosensitivity to SRS, then the use of a lower marginal dose 
may decrease the risk of tumor hemorrhage without compro-
mising LC in this group of patients. This would be particularly 
helpful when there is concern for systemic disease progression 
if the BRAF inhibitor is held.
During final manuscript preparation, we came across a study 
similar to ours presented by Kotecha and colleagues in abstract 
form (31). They reported 25 patients with MBM treated with 
SRS. BRAF-mutated patients had a significantly improved OS 
and PFS compared to BRAF wild-type patients. Of the 48 MBM 
with recurrence information available, they found a higher rate of 
in-field failure among BRAF wild-type metastases (8/20) vs. those 
that are BRAF-mutated (4/28; p = 0.04). Their results, therefore, 
corroborate our finding, also suggesting the potential impact of 
BRAF status on outcome after SRS.
Our study has several limitations. Our sample size is small 
with only 69 eligible metastases in 19 eligible patients. Despite this 
size, there were trends that could reach significance with larger 
sample sizes. Another limitation is the retrospective nature of the 
study, which inherently does not allow for control of unknown 
variables between the two groups. It is encouraging that Kotecha 
et al. recently reported similar findings. Nevertheless, confirma-
tory studies from other institutions and from larger databases 
would be required to fully assess the impact of BRAF on SRS 
outcomes. Finally, the mutation status of BRAF obtained from 
the primary site or a more accessible metastatic site was assumed 
for the intracranial tumors. Metastatic tumors may change 
molecular subtype during disease course as has been shown for 
breast cancer (32).
cOnclUsiOn
In this retrospective study, we analyzed the outcome of MBM 
treated with GK SRS and found that lesions with BRAF muta-
tion appear to have an improved LC compared to those with 
wild-type BRAF. It is unclear whether this is caused by inherent 
radiosensitivity associated with the mutation, or due to the use 
of a BRAF inhibitor. Further studies will be required to fully 
characterize the role of BRAF mutation in LC of brain metastases 
treated with SRS.
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